Evidence map›Paper›PMID 42447248›Full record

ArticleThe oncologist2026

Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer.

Jinesh S Gheeya, Raj Singh, Mingjia Li, Saman Ahmadian, Konstantin Shilo, Triparna Sen, Christian Rolfo, David P Carbone, Dwight H Owen, David R Gandara

Abstract readCase Reports
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinesh S GheeyaDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.ORCID 0000-0002-5246-6262
Raj SinghDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Mingjia LiDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Saman AhmadianDepartment of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Konstantin ShiloDepartment of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Triparna SenDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
Christian RolfoDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.ORCID 0000-0002-7860-8417
David P CarboneDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.ORCID 0000-0003-3002-1921
Dwight H OwenDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.
David R GandaraDivision of Hematology & Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, California 95817, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histologic transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a rare mechanism of resistance in anaplastic lymphoma kinase (ALK)-rearranged disease. Diagnosis is traditionally dependent on tissue biopsy, which may be limited by lesion accessibility and low disease burden. We report a case of ALK-rearranged lung adenocarcinoma that underwent small cell transformation, in which methylation-based circulating cell-free DNA (cfDNA) analysis detected a small cell lung cancer signature 5 months prior to tissue confirmation. Serial liquid biopsies demonstrated dynamic changes in tumor fraction and histologic composition that correlated with response to chemoradiation and continuation of ALK-directed therapy. This case highlights the potential utility of methylation-based liquid biopsy for early detection and longitudinal monitoring of histologic transformation in oncogene-driven NSCLC.

Indexed as

Anaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungCell Transformation, NeoplasticLung NeoplasmsSmall Cell Lung CarcinomaAgedDNA MethylationFemaleGene RearrangementHumansLiquid BiopsyALK protein, humanAnaplastic Lymphoma KinaseALK-rearranged non–small cell lung cancerliquid biopsymethylation-based cell-free DNAsmall cell transformation

Identifiers

PMID42447248
PMCPMC13407422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.